Interpace Biosciences®, Inc. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Segment Information (Tables)

Segment Information (Tables)

12 Months Ended

Dec. 31, 2014

Schedule of Segment Reporting Information, by Segment [Table Text Block]



	Commercial Services			Interpace Diagnostics			Consolidated
For the year ended December 31, 2014:
Revenue	$	118,461		$	1,474		$	119,935
Operating loss	$	(3,168	)	$	(10,302	)	$	(13,470	)
Capital expenditures	$	1,580		$	1,271		$	2,851
Depreciation and amortization expense (1)	$	1,001		$	841		$	1,842
Total assets	$	34,807		$	81,099		$	115,906
For the year ended December 31, 2013:
Revenue	$	146,534		$	—		$	146,534
Operating loss	$	(980	)	$	(457	)	$	(1,437	)
Capital expenditures	$	1,818		$	—		$	1,818
Depreciation and amortization expense (1)	$	1,190		$	—		$	1,190
Total assets	$	67,562		$	1,502		$	69,064

(1) Excludes amounts included within discontinued operations.

- Definition

Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.

+ References + Details